Company Focus
Regeneron Pharmaceuticals Inc
Latest Regeneron Pharmaceuticals Inc News
Pharmaceutical
The atopic dermatitis market across the seven major markets is forecast to nearly triple in value over the next decade, driven by advances in targeted therapies and a deeper understanding of disease mechanisms. 5 June 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Regeneron Pharmaceuticals Inc
Pharmaceutical
Sweden’s Enzymatica has appointed Sana Alajmovic as its new chief executive (CEO), succeeding Claus Egstrand, who has announced that he is stepping down from his operational role, but he will be proposed to join the company’s board of directors in order to ensure continuity. 12 August 2025
Biotechnology
Shanghai Fosun Pharma has signed a license agreement with Expedition Therapeutics, granting the latter rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. 12 August 2025
Biotechnology
Castleman’s disease (CD) refers to a group of rare lymphoproliferative disorders characterized by abnormal lymph node architecture and systemic inflammation. 12 August 2025
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Biotechnology
Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio (imsapepimut and etimupepimut 11 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has ordered label changes for bluebird bio's Skysona (elivaldogene autotemcel) due to blood cancer risks associated with the gene therapy product. 11 August 2025
Biosimilars
Chinese drugmaker Kexing Biopharm has entered a strategic partnership with US life sciences services group IQVIA, aiming to accelerate the development and international rollout of its innovative medicines and biosimilars. 11 August 2025
Biotechnology
Indian cell therapy company Eyestem Research has raised $10 million in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE. 11 August 2025
Pharmaceutical
The US Food and Drug Administration (FDA) granted accelerated approval to (Hernexeos, Boehringer Ingelheim’s Hernexeos (zongertinib), the first orally administered, targeted treatment for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. 11 August 2025
Biotechnology
Biotech start-ups around the world are still able to find sufficient backing to put sizeable rounds together, even in these times of geopolitical uncertainty and US government funding cuts, if three financings announced Thursday are anything to go by. 8 August 2025
Latest In Brief for Regeneron Pharmaceuticals Inc
Biotechnology
US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first gene-agnostic therapy seeking approval for retinitis pigmentosa (RP). 15 July 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze